GB201620968D0 - Adenovirus polynucleotides and polypeptides - Google Patents

Adenovirus polynucleotides and polypeptides

Info

Publication number
GB201620968D0
GB201620968D0 GBGB1620968.6A GB201620968A GB201620968D0 GB 201620968 D0 GB201620968 D0 GB 201620968D0 GB 201620968 A GB201620968 A GB 201620968A GB 201620968 D0 GB201620968 D0 GB 201620968D0
Authority
GB
United Kingdom
Prior art keywords
polypeptides
adenovirus
polynucleotides
adenovirus polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1620968.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1620968.6A priority Critical patent/GB201620968D0/en
Publication of GB201620968D0 publication Critical patent/GB201620968D0/en
Priority to EA201991116A priority patent/EA201991116A1/ru
Priority to AU2017371944A priority patent/AU2017371944B2/en
Priority to PCT/IB2017/057738 priority patent/WO2018104911A1/en
Priority to CA3045973A priority patent/CA3045973A1/en
Priority to MX2019006725A priority patent/MX2019006725A/es
Priority to KR1020197018883A priority patent/KR20190092471A/ko
Priority to CN201780074539.3A priority patent/CN110300597A/zh
Priority to BR112019010906A priority patent/BR112019010906A2/pt
Priority to JP2019530815A priority patent/JP2020511114A/ja
Priority to ARP170103442A priority patent/AR110502A1/es
Priority to EP17838152.1A priority patent/EP3551224A1/en
Priority to BE2017/5910A priority patent/BE1025029B1/fr
Priority to US16/466,683 priority patent/US11414679B2/en
Priority to IL266942A priority patent/IL266942A/en
Priority to US17/742,221 priority patent/US11795478B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1620968.6A 2016-12-09 2016-12-09 Adenovirus polynucleotides and polypeptides Ceased GB201620968D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1620968.6A GB201620968D0 (en) 2016-12-09 2016-12-09 Adenovirus polynucleotides and polypeptides
US16/466,683 US11414679B2 (en) 2016-12-09 2017-12-07 Adenovirus polynucleotides and polypeptides
KR1020197018883A KR20190092471A (ko) 2016-12-09 2017-12-07 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
BR112019010906A BR112019010906A2 (pt) 2016-12-09 2017-12-07 polinucleotídeo, vetor, adenovírus, composição, célula, polipeptídeo, uso dos mesmos, e, métodos para induzir e para elicitar uma resposta imune e para profilaxia ou tratamento em um indivíduo.
PCT/IB2017/057738 WO2018104911A1 (en) 2016-12-09 2017-12-07 Adenovirus polynucleotides and polypeptides
CA3045973A CA3045973A1 (en) 2016-12-09 2017-12-07 Adenovirus polynucleotides and polypeptides
MX2019006725A MX2019006725A (es) 2016-12-09 2017-12-07 Polinucleotidos y polipeptidos de adenovirus.
EA201991116A EA201991116A1 (ru) 2016-12-09 2017-12-07 Полинуклеотиды и полипептиды аденовируса
CN201780074539.3A CN110300597A (zh) 2016-12-09 2017-12-07 腺病毒多核苷酸和多肽
AU2017371944A AU2017371944B2 (en) 2016-12-09 2017-12-07 Adenovirus polynucleotides and polypeptides
JP2019530815A JP2020511114A (ja) 2016-12-09 2017-12-07 アデノウイルスポリヌクレオチド及びポリペプチド
ARP170103442A AR110502A1 (es) 2016-12-09 2017-12-07 Polinucleótidos y polipéptidos de adenovirus
EP17838152.1A EP3551224A1 (en) 2016-12-09 2017-12-07 Adenovirus polynucleotides and polypeptides
BE2017/5910A BE1025029B1 (fr) 2016-12-09 2017-12-07 Polynucleotides et polypeptides d' adenovirus
IL266942A IL266942A (en) 2016-12-09 2019-05-28 Adenovirus polynucleotides and polypeptides
US17/742,221 US11795478B2 (en) 2016-12-09 2022-05-11 Adenovirus polynucleotides and polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1620968.6A GB201620968D0 (en) 2016-12-09 2016-12-09 Adenovirus polynucleotides and polypeptides

Publications (1)

Publication Number Publication Date
GB201620968D0 true GB201620968D0 (en) 2017-01-25

Family

ID=58222021

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1620968.6A Ceased GB201620968D0 (en) 2016-12-09 2016-12-09 Adenovirus polynucleotides and polypeptides

Country Status (15)

Country Link
US (2) US11414679B2 (cg-RX-API-DMAC7.html)
EP (1) EP3551224A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020511114A (cg-RX-API-DMAC7.html)
KR (1) KR20190092471A (cg-RX-API-DMAC7.html)
CN (1) CN110300597A (cg-RX-API-DMAC7.html)
AR (1) AR110502A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017371944B2 (cg-RX-API-DMAC7.html)
BE (1) BE1025029B1 (cg-RX-API-DMAC7.html)
BR (1) BR112019010906A2 (cg-RX-API-DMAC7.html)
CA (1) CA3045973A1 (cg-RX-API-DMAC7.html)
EA (1) EA201991116A1 (cg-RX-API-DMAC7.html)
GB (1) GB201620968D0 (cg-RX-API-DMAC7.html)
IL (1) IL266942A (cg-RX-API-DMAC7.html)
MX (1) MX2019006725A (cg-RX-API-DMAC7.html)
WO (1) WO2018104911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
CN111108203A (zh) * 2017-07-17 2020-05-05 葛兰素史密丝克莱恩生物有限公司 狂犬病病毒抗原构建体
SG11202003058UA (en) * 2017-10-16 2020-04-29 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
WO2021156489A1 (en) * 2020-02-05 2021-08-12 Imophoron Limited Engineered polypeptides derived from variable domain of adenovirus penton base
EP4133090A1 (en) * 2020-04-07 2023-02-15 Lung Biotechnology PBC Adenoviral expression vector and methods and cell lines for production
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
GB202016139D0 (en) * 2020-10-12 2020-11-25 Ospedale San Raffaele Polynucleotide
JP2025523458A (ja) * 2022-06-22 2025-07-23 アスクバイオ インコーポレイテッド アデノウイルスに基づく核酸およびその方法
CN121816424A (zh) * 2023-08-11 2026-04-07 拜奥卡德联合股份公司 用于生产基于腺相关病毒(AAV)的载体(变体)的腺病毒E2a基因的修饰的序列

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO2000011140A1 (en) 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
JP4814800B2 (ja) * 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
CA2610919C (en) 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
SI1957528T1 (sl) 2005-11-30 2013-02-28 University Of Copenhagen Nukleotidno cepivo
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
CN102131920B (zh) * 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
SI2865387T1 (sl) 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
WO2016198621A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Also Published As

Publication number Publication date
AU2017371944B2 (en) 2020-07-02
IL266942A (en) 2019-07-31
US20190300905A1 (en) 2019-10-03
WO2018104911A1 (en) 2018-06-14
US11414679B2 (en) 2022-08-16
BR112019010906A2 (pt) 2019-10-01
CA3045973A1 (en) 2018-06-14
KR20190092471A (ko) 2019-08-07
MX2019006725A (es) 2019-08-22
US11795478B2 (en) 2023-10-24
BE1025029B1 (fr) 2018-10-10
BE1025029A1 (fr) 2018-10-02
JP2020511114A (ja) 2020-04-16
AU2017371944A1 (en) 2019-06-20
EA201991116A1 (ru) 2019-12-30
AR110502A1 (es) 2019-04-03
US20220275397A1 (en) 2022-09-01
EP3551224A1 (en) 2019-10-16
CN110300597A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
IL266942A (en) Adenovirus polynucleotides and polypeptides
IL256121A (en) Adenovirus polynucleotides and polypeptides
ZA202002184B (en) Adenovirus and uses thereof
ZA202002191B (en) Adenovirus and uses thereof
IL275307B (en) Syntac polypeptides and their uses
IL262482A (en) New polypeptides
ZA201802261B (en) Polypeptides
ZA201706420B (en) Transposase polypeptides and uses thereof
IL254577A0 (en) polypeptides
GB201713765D0 (en) Modified adenovirus
GB201611530D0 (en) Novel polypeptides
IL274220A (en) Adenovirus and its uses
IL270091A (en) Ketoroductase polypeptides and polynucleotides
SG11201706882VA (en) Polypeptides
ZA201704366B (en) Il-17a-binding polypeptides
GB201707139D0 (en) Polypeptides
GB201410031D0 (en) Polypeptides and uses thereof
ZA201708159B (en) Adenovirus polynucleotides and polypeptides
GB201514772D0 (en) Adenovirus polynucleotides and polypeptides
GB201510357D0 (en) Adenovirus polynucleotides and polypeptides
GB201613143D0 (en) Polypeptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201511958D0 (en) Polypeptides, polynucleotides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)